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Abstract
Background
Traumatic brain injury (TBI) is a complex disorder that is traditionally stratified based on clini-
cal signs and symptoms. Recent imaging and molecular biomarker innovations provide
unprecedented opportunities for improved TBI precision medicine, incorporating patho-ana-
tomical and molecular mechanisms. Complete integration of these diverse data for TBI diag-
nosis and patient stratification remains an unmet challenge.
Methods and findings
The Transforming Research and Clinical Knowledge in Traumatic Brain Injury (TRACK-TBI)
Pilot multicenter study enrolled 586 acute TBI patients and collected diverse common data
elements (TBI-CDEs) across the study population, including imaging, genetics, and clinical
outcomes. We then applied topology-based data-driven discovery to identify natural sub-
groups of patients, based on the TBI-CDEs collected. Our hypothesis was two-fold: 1) A
machine learning tool known as topological data analysis (TDA) would reveal data-driven
patterns in patient outcomes to identify candidate biomarkers of recovery, and 2) TDA-iden-
tified biomarkers would significantly predict patient outcome recovery after TBI using more
traditional methods of univariate statistical tests. TDA algorithms organized and mapped the
data of TBI patients in multidimensional space, identifying a subset of mild TBI patients with
a specific multivariate phenotype associated with unfavorable outcome at 3 and 6 months
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after injury. Further analyses revealed that this patient subset had high rates of post-trau-
matic stress disorder (PTSD), and enrichment in several distinct genetic polymorphisms
associated with cellular responses to stress and DNA damage (PARP1), and in striatal
dopamine processing (ANKK1, COMT, DRD2).
Conclusions
TDA identified a unique diagnostic subgroup of patients with unfavorable outcome after mild
TBI that were significantly predicted by the presence of specific genetic polymorphisms.
Machine learning methods such as TDA may provide a robust method for patient stratifica-
tion and treatment planning targeting identified biomarkers in future clinical trials in TBI
patients.
Trial Registration
ClinicalTrials.gov Identifier NCT01565551
Introduction
Traumatic brain injury (TBI) annually produces 52,000 deaths, 257,000 hospitalizations and
2.2 million emergency visits in the United States (US) alone [1]. Even though TBI is a major
cause of death and disability, it is currently diagnosed with crude, symptom-based tools, and
few targeted treatments exist. During the initial TBI event, biomechanical forces interact with
complex tissue geometry to produce nonlinear microforces, resulting in distributed multifocal
lesions throughout the brain [2]. At a cellular level TBI results in membrane disruption, cell
death, and diffuse axonal injury, accompanied by a cascade of secondary injury mechanisms
that evolve over time [3,4]. These complex biological processes produce a poorly understood
constellation of clinical symptomatology, with multifaceted impairments ranging from motor
deficits to debilitating neurocognitive and personality changes. Because of the significant, mul-
timodal heterogeneity of post-TBI symptoms, post-event treatment and follow-up pose a sig-
nificant challenge. Some of these impairments may even go undiagnosed, particularly in the
milder categories of TBI that include concussion.
One approach to better understand and to treat symptoms of TBI is to identify biomarkers
for vulnerable patient subpopulations. However, defining clear central nervous system (CNS)
biomarkers has historically been challenging, given the heterogeneity of TBI [5]. Fortunately,
recent innovations in molecular biology and imaging provide unprecedented opportunities
for data-rich phenotyping [6]. To aid TBI precision medicine, the National Institutes of
Health-National Institute of Neurological Disorders and Stroke (NIH-NINDS) launched a
major initiative to define TBI common data elements (TBI-CDEs). Hence, there is now a con-
certed and collaborative effort among researchers to define, collect, and analyze TBI-CDEs.
The multicenter Transforming Research and Clinical Knowledge in TBI Pilot (TRACK-TBI
Pilot) study provides the first prospective test of the feasibility and utility of the NINDS TBI
CDEs [6,7]. As part of the effort, TRACK-TBI Pilot developed an information commons from
the CDEs collected prospectively for 586 acute TBI patients from 3 level 1 trauma centers in
the US.
Given the highly detailed and multi-scalar data in TRACK-TBI Pilot, we approached the
problem from a model-free perspective, using an approach that has been developed from the
Visualizing TBI phenotypes
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application of TDA on real-world datasets [8–10]. TDA is a machine learning data analytic
used to cluster patients based on functional outcome data to derive novel insights into disease
mechanisms (Fig 1). To date TDA has been successfully applied to biological datasets to dis-
cover novel insights including identification of subpopulations of cancer, identification of
genomic biomarkers, disease association, RNA folding, viral evolution, immunology, diabetes,
and preclinical spinal cord injury and TBI[10–16]. The current study aims to test the following
hypotheses in the TRACK-TBI Pilot information commons: 1) TDA will reveal data-driven
patterns in patient outcomes to identify candidate biomarkers of recovery following TBI, and
2) TDA-identified biomarkers predict patient outcome recovery after TBI.
Methods
TBI Common Data Elements (TBI-CDEs) and the TRACK-TBI pilot study
The NIH/NINDS developed the TBI-CDEs to overcome pitfalls in TBI clinical research,
including lack of standardization in data collection and analysis, inability to appropriately
stratify patients, and discordant injury types [17]. Using a consensus-based approach, NINDS
Fig 1. (A-E). Methodological work-flow for integrating diverse clinical TBI data. (A) Hypothetical
example of a spatial bi-plot of individual patients (grey points) on 2 functional endpoints after TBI (GOS-E
AND PTSD). The same approach can be applied to multiple metrics simultaneously using multivariate pattern
detectors (e.g., principal component analysis) to produce a multivariate view of function. (B) In TRACK-TBI
Pilot the same individuals (N = 586) were tracked prospectively across multiple domains (function,
biomarkers, imaging) providing connections (lines) across domains to improve patient classification using the
full syndromic space. (C) Multivariate pattern detection lens can be used to categorize (colors) patients across
all domains. (D) Patient grouping by multivariate lens. (E) Topological visualization renders patient groups into
individual nodes, colored by the multivariate lens. Edges (black lines) indicate individuals appearing in both
groups producing a syndromic map of patient clusters.
doi:10.1371/journal.pone.0169490.g001
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working groups developed standards for data capture across 4 broad domains: clinical assess-
ments and demographic information, genetics and proteomics, neuroimaging, and outcome
measures. The NINDS-CDE planning committee instructed working groups to stratify data
elements into 1 of 3 categories: ‘core’, ‘basic,’ and ‘supplemental.’[18] Core elements comprise
the most basic information: data that is absolutely fundamental to capture (e.g., gender, age).
Basic elements provide additional diagnostic detail (e.g., education level, cause of injury).
Emerging CDEs include innovative approaches that require validation before broad clinical
adoption (e.g. imaging, serial plasma biomarkers).) [19]. The multicenter prospective TRACK-
TBI Pilot study assessed the feasibility and utility of the TBI-CDEs in a prospective, limited
multicenter (3-center) clinical observational trial [7], setting the stage for large-scale multicen-
ter prospective efforts currently underway in the US and Europe [6,20].
Patient enrollment
Subject eligibility was based on presentation to any of the 3 Level-1 trauma centers [(Zucker-
berg San Francisco General Hospital (CA), University of Pittsburgh Medical Center (PA),
and University Medical Center Brackenridge (Austin, TX)] within 24 hours of injury and a
history of external force trauma to the head requiring a noncontrast head CT, in accordance
with the American College of Emergency Physicians/Centers for Disease Control (ACEP/
CDC) criterion [21]. Patients were excluded if pregnant, in custody, non-English speaking, or
on a psychiatric hold (danger to yourself or others). Between April 2010 and May 2011 the
TRACK-TBI Pilot enrolled 599 acute TBI patients; 13 subjects age<16 years were excluded
due to differences in variables recommended by CDE working groups, resulting in 586 sub-
jects in the current analysis. TRACK-TBI Pilot collected 944 raw data elements per subject.
From these, a set of 213 cleaned, well-curated endpoints were distilled for meaningful analysis.
Eligible subjects were enrolled through convenience sampling at all three sites. Institutional
Review Board (IRB) approval was obtained at all participating sites prior to study initiation.
Written informed consent was obtained from all subjects prior to enrollment in the study. For
patients unable to provide consent due to the severity of their injury, consent was obtained
from their legally authorized representative (LAR). Patients were then re-consented, if cogni-
tively able, at later inpatient and/or outpatient follow-up assessments for continued participa-
tion in the study. Children aged 13 and above provided their own written consent in addition
to written parental/guardian consent. Clinical characteristics for patients included in the study
are summarized in Table 1.
Clinical assessments and demographics
The CDE working group defined subject characteristics (i.e., demographics and social status),
subject and family history, injury- or disease-related events (e.g., mechanism of injury, second-
ary insults), and assessments and evaluations (e.g., vital signs, intracranial pressure). The
working group created a basic, intermediate, and advanced adaptation of each data element,
offering investigators flexibility in the level of detail appropriate to a given study [22]. From
the CDEs, the TRACK-TBI Pilot collected a combination of core, supplemental, and emerging
variables.
Genetic material
DNA and acute plasma samples (<24 hours) were collected using standardized protocols
developed by the NINDS TBI CDE biospecimens and biomarkers working group [23].
TRACK-TBI Pilot also followed the meticulous guidelines regarding how samples should be
obtained, processed, stored locally, stored centrally, and shipped [23].
Visualizing TBI phenotypes
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Neuroimaging
The NINDS neuroimaging working group supplied pathoanatomical definitions for 23 distinct
lesion types to be used with any imaging modality. Core variables were distinguished as the
presence or absence of individual lesions; lesion location and volumetric properties comprised
most of the supplemental category, and emergent elements encompassed lesion-specific com-
plexities. The imaging working group also provided recommendations for protocols to be used
for both CT and MRI [24,25]. A board-certified neuroradiologist examined and coded all levels
of neuroimaging variables. Recommended imaging parameters were implemented at all sites.
Outcomes
The outcomes working group delineated 12 domains of behavioral outcomes. Choosing 1 mea-
sure from 11 of the 12 domains, TRACK-TBI Pilot included a broad outcomes battery. Global
outcome was assessed using a standard endpoint, the Glasgow Outcome Scale-Extended
(GOS-E). The GOS-E is an 8-point clinical grading scheme for categorizing the outcome and
Table 1. Patient clinical characteristics.
Patient Characteristics N (%)
(N = 586)
Age (mean & standard deviation) 43.3 +/- 18.5
Sex
Female 167 (28.5%)
Race
White 491 (71.5%)
Education
Below high school 68 (12.3%)
High school graduate 320 (57.7%)
Bachelor’s and above 167 (30.1%)
Psychiatric History
Present 170 (29.0%)
Previous TBI
No 292 (52.8%)
Yes without hospitalization 103 (18.6%)
Yes with hospitalization 158 (28.6%)
Cause of Injury
Motor vehicle accident 105 (18.0%)
MCC/bike accident 108 (18.5%)
Pedestrian hit 44 (7.5%)
Fall 199 (34.1%)
Assault 94 (16.1%)
Other 33 (5.7%)
ED admission GCS
Severe (3–8) 42 (7.6%)
Moderate (9–12) 28 (5.1%)
Mild (13–15) 480 (87.3%)
ED admission head CT
Positive 259 (44.2%)
Abbreviations: TBI = traumatic brain injury, MCC = motorcycle, ED = emergency department,
GCS = Glasgow Coma Scale, CT = computed tomography.
doi:10.1371/journal.pone.0169490.t001
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disability spectrum from ‘dead’ (GOS-E = 1), lower moderate disability (GOSE = 5), to upper
good recovery (GOS-E = 8). Recovery from TBI is evidenced by achieving a higher GOS-E over
time. Supplemental cognitive and psychological assessments added to a more comprehensive
understanding of a domain, whereas tools in the last stages of validation were considered emerg-
ing [26]. TRACK-TBI Pilot administered the core and a subset of supplemental measures 3-, and
6-months after injury. Study personnel received a priori training to ensure standardization.
Topological Data Aalysis (TDA)
TDA was performed using a cloud-based analytic platform (Ayasdi, Inc. v 3.0) on 586 patients
enrolled in the TRACK-TBI pilot clinical observational trial. Patients were prospectively mea-
sured on over 900 separate variables, including the NIH/NINDs common data elements
(CDEs). TDA was applied to extract the fundamental outcome features across multiple clinical
variables, simultaneously. For the purposes of TDA, we limited our analysis to 17 CDEs based
on their clinical importance (Table 2). These 17 CDEs included CT findings, PTSD diagnosis,
and cognitive measures of processing speed and verbal learning. TDA clustered patients into
subgroups (nodes) based on similarity across the 17 measures, considered simultaneously as a
holistic unit (Fig 1). Subgroups that share at least 1 patient in common are joined by a line
(edge). The descriptive statistics of the 17 CDEs are summarized in Table 2. Missing data were
only observed in the 6-month outcome variables. Determining whether there are natural sub-
types within the TBI population based on these 17 CDEs presents an analytic problem that is
both multi-dimensional (17 dimensions) and multi-scalar (each CDE has different range,
distributional and metric features). TDA is mathematically well-suited for dealing with this
complexity (see below)[8,9,11]. Simply put, TDA uses shape-based feature detection to extract
the fundamental shape of the data-space. This shape is mathematically referred to as a ‘reeb
graph’ and represents the manifold of the outcome data space. We refer to the mapping of the
Table 2. Descriptive statistics of CDE variables included in TDA to map TBI patients into a network topology based on TBI severity.
Variables used in TDA N Missing Min Max Mean SD
CT Brain Pathology 586 0 0 1 0.44 0.50
Skull Fracture 586 0 0 1 0.22 0.41
Skull Base Fracture 586 0 0 1 0.11 0.31
Facial Fracture 586 0 0 1 0.17 0.38
Epidural Hematoma 586 0 0 1 0.05 0.22
Subdural Hematoma 586 0 0 1 0.26 0.44
Subarachnoid Hemorrhage 586 0 0 1 0.26 0.44
Contusion 586 0 0 1 0.24 0.43
Midline Shift 586 0 0 1 0.07 0.25
Cisternal Compression 586 0 0 1 0.12 0.33
Marshall CT Score 586 0 1 6 1.76 1.10
Rotterdam CT Score 586 0 1 6 2.45 0.83
PTSD Diagnosis at 6 months (DSM-IV) 338 248 0 1 0.24 0.43
PTSD Checklist-Civilian Version at 6 months 338 248 17 83 32.98 14.80
WAIS Processing Speed at 6 months 305 281 50 150 99.20 15.96
CVLT: Short Delay Cued Recall at 6 months 296 290 -4.0 2.5 -0.08 1.14
CVLT: Long Delay Cued Recall at 6 months 295 291 -3.5 2.5 -0.19 1.17
Abbreviations: CT = computed tomography, PTSD = post-traumatic stress disorder, DSM–Diagnostic and Statistical Manual of Mental Disorders,
WAIS = Wechsler Adult Intelligence Scale, CVLT = California Verbal Learning Task.
doi:10.1371/journal.pone.0169490.t002
Visualizing TBI phenotypes
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patients within the TBI-CDEs as the ‘syndromic space’ of TBI (Fig 1A–1C). We refer to the
TDA network as the TBI ‘syndromic map’ of patients within the syndromic space (Fig 1D).
TDA clustered patients using a norm correlation metric, which measures the distance
between 2 points by the Pearson correlation, given by:
NormCorrðX;YÞ ¼ 1   rðX0;Y 0Þ ½1
Where X’, Y’ are the column-wise, mean-centered, and variance normalized versions of X and
Y, and
r X;Yð Þ ¼
N
PN
i¼1 Xi Yi  
PN
i¼1 Xi
PN
i¼1 Yiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
N
P
iX2i   ð
P
iXiÞ
2
q ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
N
P
iY2i   ð
P
iYiÞ
2
q ½2
This was combined with a lens called multidimensional scaling (MDS) coordinate 1 and
MDS coordinate 2. These lenses generate a factorization of the data matrix into linearly un-
correlated components, with MDS coordinate 1 representing the highest variance, and MDS
coordinate 2 representing the second-highest variance. The patient data are mapped into a
Euclidean space, minimizing the sum of squares error, using the distance matrix rather than
the coordinates. Gower’s normalization is then applied prior to applying MDS to generate the
lens values by:
f ðXÞ   min
z
X
i;j
ðdðXi;XjÞ   L2ðZi;ZjÞÞ
2
½3
TDA then resamples the MDS space millions of times in a cloud-based supercomputer,
with overlapping sample bins of variable sizes to extract the shape of the data manifold. Bin-
ning size was set at a resolution of 30 and a gain of 3.0 (equalized). The resolution setting con-
trols the number of bin partitions patients are clustered into, similar to scaling up or down on
a microscope. Increasing the resolution increases the number of nodes in the analysis graph to
reveal more fine structure in the syndromic space, with fewer patients per node, preserving
only the strongest connections between groups of patients. Nodes that are weakly associated
tend to break apart and create smaller subgroups of patients. Gain is adjusted so that most
data points will appear in the same number of bins that the gain is set to. Increasing the gain
increases the number of connections between nodes/groups of patients to highlight relation-
ships within the data. Reducing the gain value will result in smaller groups of nodes and more
unconnected/single nodes. Equalizing the network distributes the patients evenly across all
nodes in the network.
Single Nucleotide Polymorphism (SNP) analysis
Previous bioassays from blood samples drawn from this TRACK-TBI Pilot cohort were ana-
lyzed to assess the role of specific genetic polymorphisms on patient outcome after mild TBI
with targeted, hypothesis-driven analysis of 3 SNPs associated with altered striatal dopamine
levels: ANKK1 C/T (rs1800497) [27], COMT Met/Val (rs4680) [28] and DRD2 C/T rs6277
[29] genotypes. These SNPs, along with 9 additional SNPs were incorporated in the TDA data-
set. These newly incorporated SNPs included 2 more genes associated with striatal dopamine
levels (ANKK1 C/G rs4938016, ANKK1 A/G rs11604671), the brain-derived neurotrophic fac-
tor (BDNF) gene (A/G rs6265), serotonin 5HT2A receptor (C/T rs6311), Apolipoprotein
(Apo)E-ε2 (C/T rs7412) and ApoE-ε4 (C/T rs429358), mu opioid receptor OPRM1 (A/G
rs1799971), B-cell lymphoma 2 (BCL2) gene (A/G rs17759659), and the Poly (ADP-ribose)
polymerase (PARP-1) gene (A/T rs3219119).
Visualizing TBI phenotypes
PLOS ONE | DOI:10.1371/journal.pone.0169490 March 3, 2017 7 / 19
Targeted hypothesis testing using General Linear Models (GLM)
SNPs found to be significantly enriched in the TDA-identified sub-groups of mild TBI patients
exhibiting worse GOS-E outcome between 3 and 6 months and a positive diagnosis of PTSD,
detected by the PTSD checklist, civilian version (PCL) a validated tool, were formally tested for
their influence on poor outcome after TBI, including PARP1, COMT, DRD2 and the 3 differ-
ent ANKK1 SNPs. The statistical model was designed as a repeated measures analysis of vari-
ance (ANOVA), testing the 3-way interaction between SNP, CT pathology (yes or no), and
change in GOS-E over time (3 to 6 months) performed on the full dataset. Results are reported
as both within-subject effects to tease out the influence of each polymorphism on GOS-E over
time either with or without CT pathology, as well as between-subject effects to test main effects
of each polymorphism on GOS-E pooled outcome across 3 and 6 months, either with or with-
out CT pathology. This targeted hypothesis testing was performed in SPSS v.19 (IBM) using
the general linear model command using type III sums-of-squares and a full factorial design.
Significance was assessed at p< .05.
Results
Natural subtypes of TBI population as defined by CDEs in a TDA
network
The generated TBI syndromic map consisted of multiple sub-networks comprising of 434 clus-
ters (from 586 patients and 17 CDEs). Similar patients are grouped as a node (Fig 1D), with
similarity defined topologically, and in a multivariate fashion from all the CDEs used in the
analysis. Similar nodes are close together and joined by an edge (Fig 1E). In this way patient
differences are graded by location across the syndromic map. The emergence of distinct sub-
networks reflects distinct subpopulations of TBI patients. We statistically explored each sub-
network to understand which CDEs play the most significant role in defining similarity and
dissimilarity among patient sub-clusters.
The TBI syndromic map reveals that patients with acute pathological findings on CT (Fig
2A) and MR (Fig 2B) scans belonged to the same sub-networks, indicating that CDEs used in
the analysis were able to cluster more severely injured TBI subpopulations together (red nodes
on right half of network). On the other hand, the left sides of the connected sub-networks con-
tained patients that were CT-negative and mostly MR-negative. (Fig 2A and 2B, blue clusters).
The TBI syndromic map revealed relationships between patients as defined by the CDEs in a
continuously-graded manner across multiple dimensions including Glasgow Coma Score
(GCS), the Marshall CT score [30], Rotterdam CT score [31], and the presence of individual
CT features, both categorical and quantitative. In addition, a clear CT-negative sub-network
emerged with corresponding high GCS, indicating mild TBI (data not shown).
Mapping of TBI severity and long-term clinical outcome measures
Fig 2 shows the network of patients clustered on the 17 CDEs using TDA. Color schemes rep-
resent the range of values for the labeled measure, including the presence of CT positive find-
ings (Fig 2A), MRI positive findings (Fig 2B), a positive diagnosis of PTSD according to DSM
IV criteria (Fig 2C). Red nodes and connections in the network highlight positive findings for
these measures, showing a clear distinction between the left (blue) and the right (red) portions
of the network. Our initial observation showed that the majority of patients with a diagnosis of
PTSD did not show substantial brain pathology measured by either CT or MRI. When the net-
work was colored by the GOS-E at both 3 months (Fig 2D) and 6 months (Fig 2E) after TBI,
these patients with a positive PTSD diagnosis and no obvious brain pathology (N = 19) did
Visualizing TBI phenotypes
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show substantial functional deficits compared to the other CT-/MR- patients (N = 43) (circled
area of the network). Data-driven exploration of this region of the network revealed a signifi-
cant enrichment of the PARP1 SNP (Fig 2F) measured in these patients, not previously
reported by the TRACK-TBI Pilot investigators. Results from previously identified genetic
polymorphisms for ANKK1 [27], COMT [28] and DRD2 [29] were confirmed to have an
impact on outcome deficits in patients with TBI (Figures in S1–S3 Figs, Tables in S1–S6
Tables).
In order to formally test the hypothesis that the PARP1 SNP was a significant predictor of
GOS-E recovery in patients with mild TBI, we performed an independent analysis on the full
dataset using a 3-way mixed general linear model with repeated measures. This analysis was
structured as a balanced factorial design testing the impact of the following factors on GOS-E
recovery: Time (repeated measure; 3 vs. 6 months), CT findings (between-subjects; yes/no)
and PARP1 genotype (between subjects: AA, AT, TT). Significant between-subject effects were
detected in the 3-way analysis: time by CT by PARP1 genotype interaction (N = 122 patients,
PARP1 A/A (n = 33), A/T (n = 44), T/T (n = 45), p = 0.019). Patients with the T/T and A/T
genotypes performed worse over time on the GOS-E compared with patients with the A/A
genotype in the patients with no CT pathology (Fig 3, Tables 3 and 4). Clinical characteristics
of patients in the TDA-selected subgroup circled in Fig 2 (N = 37) are summarized in Table 5,
alongside clinical characteristics for all patients with data collected and analyzed for the PARP1
SNP (N = 298). The TDA-selected patient group was slightly younger (41.1 ± 14.2 TDA group,
vs 43.5 ± 18.2 all PARP1 group), with 6.1% fewer females, 22.4% fewer Caucasians, and roughly
Fig 2. (A-F). TBI CDE network topology identifies the PARP1 SNP as a candidate predictor of GOS-E
deficits in mild TBI. Patients with TBI were mapped into a TDA network, highlighting color schemes for CT (A)
and MRI (B) pathology and whether they had a confirmed diagnosis of PTSD (DSM IV) at 6 months post-TBI
(C). Patients in the circled regions of the network were identified due to substantial dysfunction measured by
the GOS-E both at 3 months (D) and 6 months (E) post-TBI, compared with other patients in the network with
no CT pathology and no diagnosis of PTSD. Data-driven exploration of these patients in the network revealed a
significant categorical enrichment for the PARP1 SNP (F), particularly the heterozygous allele (A/T). Heat map
represents range of numerical values for each measure: Panels A-C yes (1 = red) vs, no (0 = blue); Panels D-E
GOS-E range from less than 3 (blue) to 8 (red); Panel F PARP1 allele A/A = 1 = blue, A/T = 2 = yellow/green, T/
T = 3 = red.
doi:10.1371/journal.pone.0169490.g002
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6% less likely to have finished high school or college. TDA selected patients also had 15% less
previous psychiatric history, however were more likely to have a previous TBI, either with
(28.9%) or without hospitalization (9.2%), and were 22% more likely to have received their TBI
from an assault.
Hypothesis testing of the interaction between CT pathology and the ANKK1 SNP allele on
GOS-E outcome over time revealed a significant 3-way interaction for ANKK1 Gly422Arg
(rs4938016) only, and a significant difference in GOS-E scores at both 3 and 6 months for
patients with a positive head CT for ANKK1 Gly318Arg (rs11604671). However, these differ-
ences were not found to significantly change over time (Figure in S1 Fig, Tables in S1 and S2
Tables). Hypothesis testing of the interaction between CT pathology and the COMT SNP allele
on GOS-E outcome over time revealed both a significant influence of COMT on GOS-E recov-
ery over time, and a 3-way interaction of GOS-E recovery time with the SNP allele and pres-
ence/absence of CT pathology, specifically in patients with a negative head CT (Figure in S2
Fig, Tables in S3 and S4 Tables). Hypothesis testing of the interaction between CT pathology
and the DRD2 SNP allele on GOS-E outcome over time revealed a significant influence of
DRD2 on GOS-E at 3- and 6-months post TBI; however, this was only detected in patients
with a positive head CT and did not significantly change over time (Figure in S3 Fig, Tables in
S5 and S6 Tables).
Fig 3. (A-B). Hypothesis testing of PARP1 genetic polymorphism influence on GOS-E deficits in mild
TBI. GOS-E scores between 3 and 6 months post-TBI were plotted for patients who were CT negative (A) or
CT positive (B), based on the SNP allele expressed (A/A = blue, A/T = yellow/green, T/T = red). Hypothesis
testing of the interaction between CT pathology and the SNP allele over time revealed a significant 3-way
interaction; however, no significance was detected at each time point individually. Only change in GOS-E over
time was significant in patients with a negative head CT.*p < .05.
doi:10.1371/journal.pone.0169490.g003
Table 3. General linear model statistics for PARP1 SNP interaction with CT pathology on GOS-E recovery.
CT Pathology x SNP Interactions
Source GOSE Score (3M) GOSE Score (6M) GOSE Score (3M to 6M
Change)
SS df MS F Sig. SS df MS F Sig. SS df MS F Sig.
PARP1 (rs3219119) .19 2 .09 .03 .97 3.16 2 1.58 .45 .64 1.80 2 .90 .81 .45
CT Pathology x PARP1 (rs3219119) 3.66 2 1.83 .54 .58 11.00 2 5.50 1.57 .21 8.94 2 4.47 4.03 *.02
Multiple Comparisons (Tukey HSD posthoc test) A/A vs A/T NT A/A vs A/T NT A/A vs A/T 0.47
A/A vs T/T NT A/A vs T/T NT A/A vs T/T 0.57
A/T vs A/A NT A/T vs A/A NT A/T vs A/A 0.47
A/T vs T/T NT A/T vs T/T NT A/T vs T/T 0.98
T/T vs A/A NT T/T vs A/A NT T/T vs A/A 0.57
T/T vs A/T NT T/T vs A/T NT T/T vs A/T 0.98
Abbreviations: SS = Type III Sum of Squares, df = degrees of freedom, MS = mean square, NT = not tested,
* = statistical significance.
doi:10.1371/journal.pone.0169490.t003
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TDA uncovered a subgroup of mild TBI individuals with poorer outcome, associated with
increased PTSD rates and specific single-nucleotide polymorphisms (SNPs) associated with
DNA damage and brain dopamine processing. The results provide proof-of-concept for appli-
cation of multi-scalar big-data analytics to improve TBI precision medicine
Discussion
TDA applied to data from multiple CT and MR imaging and neuropsychological domains
captured the multidimensional locus of individual patients within the TBI syndromic space.
Rapid mapping of TBI outcome onto the TDA-syndromic space revealed that mild TBI can be
Table 5. Clinical characteristics of TDA-identified patient subgroup with PARP1 SNP (N = 37) along-
side to all patients with PARP1 SNP (N = 298).
Patient Characteristics All PARP1 Patients (N = 298) TDA Subgroup (N = 37)
Age (mean & standard deviation) 43.5 +/- 18.2 41.1 +/- 14.2
Sex
Female 91 (30.5%) 9 (24.4%)
Race
White 252 (84.6%) 23 (62.2%)
Education
Below high school 27 (9.1%) 9 (25%)
High school graduate 167 (56.0%) 18 (50%)
Bachelor’s and above 93 (31.2%) 9 (25%)
Psychiatric History
Present 93 (31.2%) 6 (16.2%)
Previous TBI
No 152 (51.0%) 6 (16.2%)
Yes without hospitalization 53 (17.8%) 10 (27.0%)
Yes with hospitalization 83 (27.9%) 21 (56.8%)
Cause of Injury
Motor vehicle accident 50 (16.8%) 3 (8.1%)
MCC/bike accident 55 (18.5%) 5 (13.5%)
Pedestrian hit 24 (6.0%) 2 (5.4%)
Fall 107 (35.9%) 11 (29.7%)
Assault 47 (15.8%) 14 (37.8%)
Other 14 (4.7%) 2 (5.4%)
ED admission GCS
Severe (3–8) 26 (8.7%) 0 (0%)
Moderate (9–12) 13 (4.4%) 0 (0%)
Mild (13–15) 230 (77.2%) 37 (100%)
ED admission head CT
Positive 144 (48.3%) 0 (0%)
PARP1 SNP
A/A 67 (22.5%) 9 (37.5%)
A/T 116 (38.9%) 9 (37.5%)
T/T 115 (38.6%) 6 (25%)
Abbreviations: PARP1 = Poly [ADP-ribose] polymerase 1, TDA = topological data analysis, TBI = traumatic
brain injury, MCC = motorcycle, ED = emergency department, GCS = Glasgow Coma Scale, CT = computed
tomography, SNP = single nucleotide polymorphism.
doi:10.1371/journal.pone.0169490.t005
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stratified into multiple subgroups that have differentiated outcome. A large subpopulation of
mild TBI subjects showed poor recovery and tendency to deteriorate from 3–6 months post-
injury (Fig 2D and 2E). These same individuals had very high rates of PTSD (Fig 2C) and sig-
nificant enrichment in the heterozygous allele of the PARP1 SNPs (Fig 2F) that is associated
with cellular responses to stress and DNA damage [32,33].
TDA improves upon traditional outcome-prediction approaches for TBI that have relied
on regression modeling of multiple predictors with respect to a single ‘gold-standard’ outcome
measure (e.g., the GOS-E). By simultaneously leveraging the full information provided by all
outcomes, TDA and related big-data approaches have potential to improve diagnosis and ther-
apeutic targeting. For example, CT features and neuropsychiatric batteries provided alternative
views of injury severity within the topological syndromic map (Fig 2), and considering each of
these pieces of information in isolation would provide only a limited view of the full syndrome
of TBI. Therefore, once the TBI syndromic space was established using the pre-selected CDEs
(Table 2), we were able to harness this full set of information for all patients to discover novel
predictors of recovery following TBI, including several SNPs. The most striking genetic bio-
marker finding was that PARP1 predicted recovery in patients with a negative head CT, who
would be considered to have a mild TBI (mTBI). Previous studies have implicated PARP1 as a
useful therapeutic target in humans with TBI, particularly in patients with severe TBI that are
enriched for A/A allele [32]. Additionally, attempts to inhibit PARP1 in rat models of TBI
have shown promise in helping to reduce cell death [33]. Therefore, PARP1 may be a useful
biomarker in mTBI patients when considering patient trajectories and how to maximize
recovery in patients presenting with this particular A/T SNP (rs3219119) of the PARP1 gene.
TDA also confirmed the influence of genes involved in dopamine processing reported pre-
viously in TRACK-TBI Pilot patients for ANKK1 [27] (Figure in S1 Fig, Tables in S1 and S2
Tables) and COMT [28] (Figure in S2 Fig, Tables S3 and S4 Tables), as well as the novel find-
ings of an influence of the DRD2 SNP C/C allele associated with better recovery of GOS-E in
patients with a positive head CT (Figure in S3 Fig, Tables in S5 and S6 Tables), however recent
findings have suggested that the T/T allele may be predictive of better recovery on verbal learn-
ing tasks after correcting for injury severity [29]. These genes represent divergent molecular
mechanisms that result in lowered brain dopamine signaling. ANKK1 T/T is associated with a
40% reduction in the DRD2 receptor [34], whereas the rs4680 SNP encodes for the Met158Val
locus of COMT, and the G/G genotype has been associated with lower dopamine levels due to
the increase in enzymatic activity [35]. Previous studies have investigated the effect of this
mutation on personality traits, dubbing the resulting phenotype as “warrior” compared to its
“worrier” counterpart. The “warrior” phenotype is associated with higher concentration,
memory, and cognitive function with mixed reports on the ability to emotionally process sti-
muli. Specifically, there have been multiple studies linking the rs4680 G/G genotype with
schizophrenia [36] and lower drug responsiveness for antidepressants and anti-narcoleptics
[37,38]. The association of TBI outcome to these genotypes may be due to decreased dopamine
levels rather than the specific biomolecular mechanism, leaving still unanswered questions
regarding the inherent predisposition to outcome and drug responsiveness of individuals suf-
fering traumatic brain injuries.
Taken together the results indicate that, COMT and PARP1 may be useful biomarkers in a
clinical prediction model to determine whether patients with an initial diagnosis of a mild TBI
will develop significant functional deficit as measured on the GOS-E. ANKK1 and DRD2, on
the other hand, may be useful biomarkers in a clinical prediction model for severe TBI, and
warrants further investigation and cross-validation in a larger patient cohort to test whether
mitigating the downstream effects of these genetic variants will improve outcome following
TBI.
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The present findings illustrate the value of TDA for expanding upon traditional diagnostic
and prognostic tools for TBI. TDA exhibits several benefits as compared with regression meth-
ods, which perform poorly with numerous inter-correlated (multi-collinear) variables. In a
regression context, multi-collinearity can lead to over-fitting to a particular dataset, limiting
diagnostic value for distinct patient populations. In addition, traditional multiple regression
models for TBI have been constructed to explain the variance of a single ‘gold standard out-
come,’ for example the GOS-E. Such approaches ignore the fact that TBI outcome is intrinsi-
cally multifaceted. The most precise patient information is captured by considering all of the
domains (e.g., psychological, cognitive) of outcome simultaneously, as is possible with TDA.
Finally, traditional statistical approaches are designed to maximize the variance explained
(predicted) in outcome and their performance is benchmarked by assessing value added over
alternative/competing models. TDA does not suffer from these limitations because it is funda-
mentally focused on extracting the most robust shape (persistent homology) [8,9] across multi-
ple alternative data views through numerous dimensions, different patient clustering
algorithms, and patient subpopulations. In essence, TDA provides direct visualization of the
shape of multidimensional TBI, enabling rapid insight-discovery not achievable through tradi-
tional analytics.
TDA and similar integrative analytics hold great promise to further propel recent advances
in the use of novel molecular biomarkers, imaging biomarkers, and psychosocial outcomes for
TBI [6,7,39–41]. To develop targeted therapeutic interventions, TBI clinician-researchers face
the complex task of stratifying patients based on multifaceted information, and integrating
information about TBI is fundamentally a data-intensive undertaking that could benefit from
the application of advanced statistical pattern-detection approaches for enhanced decision sup-
port. Through integrative analytics of TRACK-TBI Pilot and similar datasets from other CNS
diseases, TDA may help realize the potential of precision medicine to rapidly and accurately
classify TBI and to identify subpopulations to target with precision medicine approaches.
Supporting information
S1 Fig. ANKK1 SNP distribution in TDA network and hypothesis testing on GOS-E recov-
ery between 3 and 6 months post-TBI. (A) Distribution of 3 separate ANKK1 SNPs in the
TDA network. (B) GOS-E scores between 3 and 6 months post-TBI were plotted for patients
who were either CT negative or CT positive, grouped based on the SNP allele expressed.
Hypothesis testing of the interaction between CT pathology and the ANKK1 SNP allele on
GOS-E outcome over time revealed a significant 3-way interaction for ANKK1 Gly422Arg
(rs4938016) only, and a significant difference in GOS-E scores at both 3 and 6 months for
patients with a positive head CT for ANKK1 Gly318Arg (rs11604671). However, these differ-
ences were not found to significantly change over time. p< .05.
(TIF)
S2 Fig. COMT SNP distribution in TDA network and hypothesis testing for impact on
GOS-E recovery between 3 and 6 months post-TBI. (A) Distribution of the COMT SNP in
the TDA network. (B) GOS-E scores at 3 and 6 months post-TBI were plotted for patients who
were CT negative or CT positive, group based on the SNP allele expressed (Met/Met = blue,
Met/Val = yellow/green, Val/Val = red). Hypothesis testing of the interaction between CT
pathology and the COMT SNP allele on GOS-E outcome over time revealed both a significant
association of COMT with GOS-E recovery over time, and a 3-way interaction of GOS-E
recovery with the SNP allele and presence/absence of CT pathology, specifically in patients
with negative head CT. # p< .05 compared to both groups.
(TIF)
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S3 Fig. DRD2 SNP distribution in TDA network and hypothesis testing on GOS-E recov-
ery between 3 and 6 months post-TBI. (A) Distribution of the DRD2 SNP in the TDA net-
work. (B) GOS-E scores between 3 and 6 months post-TBI were plotted for patients who were
CT negative or CT positive, group based on the SNP allele expressed (C/C = blue, C/
T = yellow/green, T/T = red). Hypothesis testing of the interaction between CT pathology and
the DRD2 SNP allele on GOS-E recovery revealed a significant association of DRD2 with
GOS-E at 3 and 6 months post TBI, however this was only detected in patients with a positive
head CT and did not significantly change over time. p< .05.
(TIF)
S1 Table. General linear model statistics for ANKK1 SNP interaction with CT pathology
on GOS-E recovery.
(DOCX)
S2 Table. General linear model statistics for ANKK1 SNP interaction on GOS-E recovery
by presence or absence of CT pathology.
(DOCX)
S3 Table. General linear model statistics for COMT SNP interaction with CT pathology on
GOS-E recovery.
(DOCX)
S4 Table. General linear model statistics for COMT SNP interaction on GOS-E recovery
by presence or absence of CT pathology.
(DOCX)
S5 Table. General linear model statistics for DRD2 SNP interaction with CT pathology on
GOS-E recovery.
(DOCX)
S6 Table. General linear model statistics for DRD2 SNP interaction on GOS-E recovery by
presence or absence of CT pathology.
(DOCX)
S1 Dataset. Minimal dataset of variables used to generate and color the TDA network. Var-
iables included in this minimal dataset are those described in Table 2 as well as GOS-E and
selected SNPs for PARP1, ANKK1, COMT and DRD2 used for hypothesis testing. The first
column of the dataset is the global unique identifier for the TRACK-TBI pilot dataset, which
can be used to link to additional variables from these patients in the full dataset stored in the
Federal Interagency Traumatic Brain Injury Research (FITBIR) informatics system (https://
fitbir.nih.gov/) and the One Mind Portal (http://onemind.org/Our-Solutions/One-Mind-
Portal). Access to the full dataset can be requested by qualified researchers through these data
portals.
(XLSX)
S1 Metadata. Relevant metadata for S1 Dataset to understand description and value ranges
and codes for each variable used to generate and color the TDA network. Variables listed in
column A of the S1 Metadata file are copied and transposed from the first row of variables in
the S1 Dataset, and accompanied by definitions and value ranges and ordinal codes for each
variable.
(XLSX)
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